Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases

Bibliography

• Kim KJ, Lee KS, Cho HJ, et al. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol 2014;45(2):285-93
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Abd Al Samid M, Al-Ramadi BK, Elkord E. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther 2014;14(7):931-45
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299-308
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114(8):1537-44
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012;12(10):1383-97
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014;63(1):67-72
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013;123(6):2447-63
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 2013;110(44):17945-50
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 2014;63(2):81-99
   PubMed Web of Science ®Google Scholar
• Battaglia A, Buzzonetti A, Martinelli E, et al. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010;76(5):1546-53
   Google Scholar
• Battaglia A, Buzzonetti A, Monego G, et al. Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 2008;123(1):129-38
   PubMed Web of Science ®Google Scholar
• Renand A, Milpied P, Rossignol J, et al. Neuropilin-1 expression characterizes T follicular helper (Tfh) cells activated during B cell differentiation in human secondary lymphoid organs. PLoS One 2013;8(12):e85589
   Google Scholar
• Nirschl CJ, Ceccato CM, Alme A, et al. Expression of neuropilin-1 on in vivo induced regulatory T cells. J Immunother Cancer 2013;1(Supp 1):167
   Google Scholar
• Weiss JM, Bilate AM, Gobert M, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 2012;209(10):1723-42. S1
   PubMed Web of Science ®Google Scholar
• Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012;209(10):1713-22. S1-19
   PubMed Web of Science ®Google Scholar
• E XQ, Meng HX, Cao Y, et al. Distribution of regulatory T cells and interaction with dendritic cells in the synovium of rheumatoid arthritis. Scand J Rheumatol 2012;41(6):413-20
   Web of Science ®Google Scholar
• Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol 2013;4:232
   PubMed Web of Science ®Google Scholar
• Miao HQ, Lee P, Lin H, et al. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14(15):2532-9
   PubMed Web of Science ®Google Scholar
• Haixia D, Jingsong Z, Lei J, et al. Gene expression of neuropilin-1 and its receptors, VEGF/Semaphorin 3a, in normal and cancer cells. Cell Biochem Biophys 2011;59(1):39-47
   Google Scholar
• Jubb AM, Strickland LA, Liu SD, et al. Neuropilin-1 expression in cancer and development. J Pathol 2012;226(1):50-60
   PubMed Web of Science ®Google Scholar
• Kumar A, Huo S, Zhang X, et al. Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(iv) drug for prostate cancer treatment. ACS Nano 2014;8(5):4205-20
   PubMed Web of Science ®Google Scholar
• Borriello L, Montes M, Lepelletier Y, et al. Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model. Cancer Lett 2014;349(2):120-7
   Google Scholar
• Xin Y, Li J, Wu J, et al. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin Cancer Res 2012;18(21):6040-8
   Google Scholar
• Shin TH, Sung ES, Kim YJ, et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther 2014;13(3):651-61
   Google Scholar
• Liang WC, Dennis MS, Stawicki S, et al. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2007;366(3):815-29
   Web of Science ®Google Scholar
• Sugimoto N, Oida T, Hirota K, et al. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 2006;18(8):1197-209
   PubMed Web of Science ®Google Scholar
• Elkord E, Sharma S, Burt DJ, Hawkins RE. Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol 2011;140(3):218-22
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Sengupta S, Han Y, Lesniak MS. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 2011;13(12):1308-23
   PubMed Web of Science ®Google Scholar
• Zabransky DJ, Nirschl CJ, Durham NM, et al. Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One 2012;7(3):e34547
   PubMed Web of Science ®Google Scholar
• Itzhaki O, Hovav E, Ziporen Y, et al. Establishment and large-scale expansion of minimally cultured young tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 2011;34(2):212-20
   PubMed Web of Science ®Google Scholar
• Elkord E. Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation. J Immunol Methods 2009;347(1-2):87-90
   PubMed Web of Science ®Google Scholar
• Elkord E, Al-Ramadi BK. Helios expression in FoxP3(+) T regulatory cells. Expert Opin Biol Ther 2012;12(11):1423-5
   PubMed Web of Science ®Google Scholar
• Elkord E. Comment on “Expression of Helios in peripherally induced Foxp3+ regulatory T cells”. J Immunol 2012;189(2):500; author reply 00-1
   Google Scholar
• Scurr M, Ladell K, Besneux M, et al. Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(-) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. Mucosal Immunol 2014;7(2):428-39
   PubMed Web of Science ®Google Scholar
• Milpied P, Renand A, Bruneau J, et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol 2009;39(6):1466-71
   PubMed Web of Science ®Google Scholar
• Lim AY, Price P, Beilharz MW, French MA. Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy. Immunol Cell Biol 2006;84(6):530-6
   Google Scholar
• Battaglia A, Buzzonetti A, Baranello C, et al. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 2009;58(9):1363-73
   Google Scholar
• Catalano A. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 2010;185(10):6373-83
   Google Scholar
• Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002;63(12):1133-48
   Google Scholar
• Raffin C, Pignon P, Celse C, et al. Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1beta by downregulating their suppressor functions. J Immunol 2013;191(9):4619-27
   PubMed Web of Science ®Google Scholar
• Baine I, Basu S, Ames R, et al. Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J Immunol 2013;190(3):1008-16
   PubMed Web of Science ®Google Scholar
• Akimova T, Beier UH, Wang L, et al. Helios expression is a marker of T cell activation and proliferation. PLoS One 2011;6(8):e24226
   PubMed Web of Science ®Google Scholar
• Bourbie-Vaudaine S, Blanchard N, Hivroz C, Romeo PH. Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J Immunol 2006;177(3):1460-9
   Google Scholar
• Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008;28(3):402-13
   PubMed Web of Science ®Google Scholar
• Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002;3(5):477-82
   PubMed Web of Science ®Google Scholar
• Gai XD, Song Y, Li C, et al. Potential role of plasmacytoid dendritic cells for FOXP3+ regulatory T cell development in human colorectal cancer and tumor draining lymph node. Pathol Res Pract 2013;209(12):774-8
   Google Scholar
• Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012;7(5):e35981
   PubMed Web of Science ®Google Scholar
• Glinka Y, Stoilova S, Mohammed N, Prud’homme GJ. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 2011;32(4):613-21
   PubMed Web of Science ®Google Scholar
• Delgoffe GM, Woo SR, Turnis ME, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 2013;501(7466):252-6
   PubMed Web of Science ®Google Scholar
• Hansen W. Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma. Oncoimmunology 2013;2(2):e23039
   Google Scholar
• Hansen W, Hutzler M, Abel S, et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 2012;209(11):2001-16
   PubMed Web of Science ®Google Scholar
• Jia H, Cheng L, Tickner M, et al. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer 2010;102(3):541-52
   PubMed Web of Science ®Google Scholar
• Casazza A, Laoui D, Wenes M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013;24(6):695-709
   PubMed Web of Science ®Google Scholar
• Staton CA, Koay I, Wu JM, et al. Neuropilin-1 and neuropilin-2 expression in the adenoma-carcinoma sequence of colorectal cancer. Histopathology 2013;62(6):908-15
   Google Scholar
• Paoli EE, Ingham ES, Zhang H, et al. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes. J Control Release 2014;178:108-17
   PubMedGoogle Scholar
• Piechnik A, Dmoszynska A, Omiotek M, et al. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer 2013;133(6):1489-96
   PubMed Web of Science ®Google Scholar